Sis Ventures

Scotland's specialist impact investor, SIS Ventures, has appointed experienced impact finance expert Amir Rizwan as the new chair of its investment committee. Mr Rizwan, who also joins the SIS Ventures board, brings over 15 years of experience in impact investing and financial services.

The British Business Bank has made its first major deal from the £150 million Investment Fund for Scotland, with a £750,000 equity investment, through appointed fund managers Maven Capital Partners into medical technology business Carcinotech. Edinburgh-based Carcinotech has raised &poun

Scotland’s first impact investor, SIS Ventures has released its inaugural Impact Report, highlighting the positive impacts on people and planet delivered by its investee companies. Since launching the Impact First Fund in 2018, SIS Ventures has invested more than £5.6 million in 14 high-

Responsible finance provider SIS Group has seen a return to ‘business-as-usual’ as resilience funding decreased and demand for other funds reached near pre-pandemic levels, as detailed in its latest annual report. During the financial year ending 31 March 2023, the group, encompassing So

Scottish biotech firm Beta Bugs Limited, specialising in insect genetics, has garnered a £1.72 million investment to bolster its production and supply of Black Soldier Fly eggs and larvae to the insect farming sector, as a sustainable alternative to current sources of protein for animal feed.

Glasgow-based medical start-up Microplate Dx has successfully closed a £2.5 million seed funding round to accelerate the development of its point-of-care diagnostic platform. The technology aims to combat antimicrobial resistance (AMR) by quickly identifying the most effective antibiotics for

A Scottish agritech firm specialising in the next generation of green insecticides has secured a further round of investment totalling £4 million to scale up the development of its nature-inspired pesticides. Investment in SOLASTA Bio's pre-Series A funding round was led by Yield Lab Europe. O

Responsible finance provider Social Investment Scotland (SIS) has appointed community finance expert Arran Dewar as executive director of SIS Ventures. Mr Dewar joins SIS Ventures from Inspiring Scotland, a venture philanthropy organisation which aims to improve the lives people from disadvanta

Dxcover — a Glasgow-based company developing a blood test that can detect cancer at an early stage — has raised £9.7 million through a Series A investment round and grant funding. The £7.5m funding round was led by existing investors Eos Advisory LLP, Mercia Asset M

Edinburgh-based biotechnology start-up, MiAlgae, has secured further investment of £2.3m to help drive the next stage of its growth journey. Established in 2016, MiAlgae has created a solution to producing a sustainable source of Omega-3 for animal and human consumption – something which

Edinburgh-based life sciences company Carcinotech, a MedTech specialist in the manufacture of 3D printed tumours developed from cancer stem cells, primary cells, and established cell lines, has secured a £1.6 million investment from leading Scotland-based investors to accelerate commercialisat

Impact investor SIS Ventures has secured £1 million for its investment fund – Impact First - from Chroma Ventures. Chroma Ventures was created in 2021 by technology entrepreneurs Paddy Burns and Chris van der Kuyl as a broad-spectrum investment arm of their video game development studio,

Edinburgh-based ad tech company Good-Loop has closed a Series A round of £4.5 million. The funds will be used to accelerate the company’s product roadmap, including the development of new solutions aimed at reducing digital advertising’s substantial carbon footprint.

SIS Ventures has launched a second round of fundraising with the aim of attracting up to £5 million to scale up its support for Scotland’s high impact potential early-stage businesses. SIS Ventures’ Impact First fund provides the opportunity for investors to make tax-efficient fina

Glasgow-based Talking Medicines, the world’s first Artificial Intelligence (AI) driven patient intelligence company designed to meet the needs of pharma, has closed a £1.5 million funding round to support its ambitions for expansion into the US. Boston based life science investor Mark Ba